Pfizer and Avon Announce Metastatic Breast Cancer Program - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer and Avon Announce Metastatic Breast Cancer Program


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

To help increase support for people living with metastatic breast cancer and their caregivers, Pfizer and the Avon Foundation for Women have partnered to establish the Avon-Pfizer Metastatic Breast Cancer Grants Program.The partnership will award up to $1 million in grants to advocacy, academic, and other not-for-profit organizations who serve the metastatic breast cancer community. The program will support initiatives to provide information and services that help people with metastatic breast cancer navigate the medical and emotional challenges associated with their disease.

A survey commissioned by Pfizer found that more than 60% of respondents say they know little to nothing about metastatic breast cancer, which occurs when cancer spreads beyond the breast to other parts of the body, including the bones, lungs, liver and brain. The survey was the first to examine the general public’s understanding of metastatic breast cancer, which affects up to 250,000 women and men in the US. The survey results reveal a range of misperceptions about the causes, treatments, and outcomes related to metastatic breast cancer.

The Metastatic Breast Cancer Grants Program is designed to address many of the misperceptions found in the survey including 72% of respondents believe that breast cancer in the advanced stages is curable if diagnosed early and 50% of respondents believe that people with breast cancer experience disease progression because they did not take the right medicines or preventative measures.

Source: Pfizer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here